RepliCel Life Sciences Inc (REPCF)
0.0428
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
RepliCel Life Sciences Enterprise Value: 2.791M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 2.791M |
| May 02, 2024 | 2.791M |
| May 01, 2024 | 2.791M |
| April 30, 2024 | 2.791M |
| April 29, 2024 | 2.791M |
| April 26, 2024 | 2.791M |
| April 25, 2024 | 2.791M |
| April 24, 2024 | 2.791M |
| April 23, 2024 | 2.791M |
| April 22, 2024 | 2.791M |
| April 19, 2024 | 2.791M |
| April 18, 2024 | 2.791M |
| April 17, 2024 | 2.791M |
| April 16, 2024 | 2.791M |
| April 15, 2024 | 2.791M |
| April 12, 2024 | 2.791M |
| April 11, 2024 | 2.791M |
| April 10, 2024 | 2.791M |
| April 09, 2024 | 2.791M |
| April 08, 2024 | 2.791M |
| April 05, 2024 | 2.791M |
| April 04, 2024 | 2.791M |
| April 03, 2024 | 2.791M |
| April 02, 2024 | 2.791M |
| April 01, 2024 | 2.791M |
| Date | Value |
|---|---|
| March 28, 2024 | 2.791M |
| March 27, 2024 | 2.791M |
| March 26, 2024 | 2.791M |
| March 25, 2024 | 2.791M |
| March 22, 2024 | 2.791M |
| March 21, 2024 | 2.791M |
| March 20, 2024 | 2.791M |
| March 19, 2024 | 2.791M |
| March 18, 2024 | 2.791M |
| March 15, 2024 | 2.791M |
| March 14, 2024 | 2.658M |
| March 13, 2024 | 2.658M |
| March 12, 2024 | 3.032M |
| March 11, 2024 | 3.032M |
| March 08, 2024 | 2.616M |
| March 07, 2024 | 2.931M |
| March 06, 2024 | 2.931M |
| March 05, 2024 | 2.931M |
| March 04, 2024 | 2.606M |
| March 01, 2024 | 2.723M |
| February 29, 2024 | 2.593M |
| February 28, 2024 | 2.593M |
| February 27, 2024 | 3.232M |
| February 26, 2024 | 3.120M |
| February 23, 2024 | 3.120M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.160M
Minimum
Dec 31 2022
12.95M
Maximum
Feb 09 2021
5.921M
Average
5.586M
Median
Apr 24 2023
Enterprise Value Benchmarks
| Acasti Pharma Inc | 2.708M |
| Aurinia Pharmaceuticals Inc | 378.91M |
| Edesa Biotech Inc | 10.43M |
| Lexaria Bioscience Corp | 35.17M |
| InMed Pharmaceuticals Inc | -8.069M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.61M |
| Revenue (Quarterly) | 0.0659M |
| Total Expenses (Quarterly) | 0.3084M |
| EPS Diluted (Quarterly) | -0.0075 |
| Profit Margin (Quarterly) | -925.7% |
| Earnings Yield | -0.44% |
| Normalized Earnings Yield | 23.15 |